查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1985589

CAR T 细胞疗法市场：2026-2032 年全球市场预测（按适应症、细胞来源、代数、治疗线、标靶抗原和最终用户划分）。

CAR T-cell Therapy Market by Indication, Cell Source, Generation, Line Of Therapy, Target Antigen, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计 CAR-T 细胞疗法市场在 2025 年的价值为 51.9 亿美元，在 2026 年增长至 59.8 亿美元，到 2032 年达到 148.7 亿美元，复合年增长率为 16.20%。

主要市场统计数据
基准年 2025 51.9亿美元
预计年份：2026年 59.8亿美元
预测年份 2032 148.7亿美元
复合年增长率 (%) 16.20%

一份简明的 CAR T 细胞疗法策略指南，整合了科学进步、生产实际情况、监管趋势和商业性准入等方面的考量。

CAR-T细胞疗法目前正处于前沿免疫肿瘤学和复杂商业性实施的交汇点。本执行摘要对CAR-T领域的现况进行了综合分析，包括临床进展、转化创新、监管趋势、生产技术成熟度以及不断演变的医疗服务模式。本文件旨在帮助企业主管、临床负责人、投资者和政策制定者了解影响研发重点和营运决策的各项因素。

技术、监管、製造和商业变革如何重塑 CAR-T 疗法的发展路径和患者获得治疗的模式。

CAR-T细胞疗法正在经历一系列变革，这些变革并非仅仅是对产品的渐进式改进，而是从根本上改变了其研发和给药的结构。载体工程、共刺激结构域选择和抗原标靶化的进步，在拓展治疗范围的同时，也提升了其安全性和持久性。这些技术进步与製造创新相辅相成，例如分散式和自动化平台，它们缩短了生产週期，降低了每剂药物的操作复杂性。随着这些技术变革的推进，新的商业模式正在涌现，这些模式将集中化的专业知识与临床应用相结合。

应对 2025 年关税变化的营运和策略措施、重组供应链韧性、製造地决策和临床试验物流。

美国于2025年实施的新关税措施为先进细胞疗法的经济性和物流带来了特定的变数。对进口原料、一次性组件和某些生物製程设备征收的关税将增加上游工程成本，并为供应商选择带来不确定性。这种情况促使製造商和临床中心重新评估筹资策略，寻找替代供应商，并考虑加强关键供应链的垂直整合。短期内，由于合约团队需要评估关税的影响并协商修订后的条款，采购週期将会延长。

基于细分的洞察揭示了适应症、细胞来源、世代、治疗系、抗原标靶和医疗保健环境如何决定开发和商业化途径。

详细的市场细分揭示了治疗和给药领域中一些微妙的驱动因素和明显的机会领域。就适应症而言，此市场涵盖白血病（白血病本身又细分为急性淋巴性白血病和急性骨髓性白血病）、多发性骨髓瘤和非何杰金氏淋巴瘤（特别是瀰漫性大B细胞淋巴瘤、滤泡性淋巴瘤和套细胞淋巴瘤等特定临床亚型）。每种适应症都有其自身的疗效预期、安全性考量和证据要求，这些因素都会影响临床试验设计和商业化策略。就细胞来源而言，异体治疗方法具有「即用型」给药和缩短治疗启动时间的潜力，而自体疗法在个人化生产符合既定安全性和有效性先例的领域仍然十分重要。

区域法规环境、生产策略和医疗保健服务体系如何导致全球市场上 CAR-T 疗法的取得途径有差异？

区域趋势对监管预期、生产策略和医疗服务模式有着深远的影响。在美洲，密集的专科治疗中心网络、历来充满活力的风险投资生态系统以及灵活的监管路径，促进了早期临床导入和商业化策略的实施，这些策略强调本土生产和真实世界数据（REW）的生成。相较之下，欧洲、中东和非洲地区则呈现出管理体制和报销机制的多元化格局，需要针对每个地区制定具体的卫生经济学论证和立足本地的参与计画。同时，这些地区也为能够服务多个市场的区域性製造地提供了发展机会。

透过製造规模、结构创新和综合商业性支援来创造竞争优势的企业策略和合作模式。

CAR-T 生态系统中的主要企业正致力于建立多元化的产品组合，涵盖建构设计、抗原标靶化和生产流程等方面，同时积极寻求策略合作伙伴关係，以确保供应链稳定并拓展临床应用。产业相关人员正投资于模组化、自动化生产平台，以缩短週期时间并提高可重复性，并积极与学术机构和契约製造组织 (CMO) 合作，以扩大产能。多家公司正透过专注于提高持久性、降低毒性和实现多抗原标靶化以应对抗原逃脱的下一代工程技术来实现差异化竞争。

一项旨在透过加强製造业韧性、证据生成、支付方合作以及扩大检测设施，加速行业领导者永续获取的行动计划。

行业领导者应优先进行一系列合作，将科学创新与营运扩充性和市场进入准备工作相结合。首先，投资建立灵活的生产架构，支援终端来源和异体来源的工作流程，从而能够快速回应不断变化的需求和关税相关的供应波动。其次，建立健全的品质体系，并为关键试剂和一次性组件提供冗余的供应保障，以最大限度地减少生产中断，确保患者治疗计划的顺利进行。第三，透过与治疗中心和註册机构合作，加速真实世界数据（REW）的创建，记录长期疗效和安全性讯号，为医保报销谈判奠定基础。

采用透明的混合方法，结合相关人员访谈、文献整合、监管审查和营运案例研究，得出了切实可行的建议。

本研究整合了一手和二手资料，以当代科学和商业性实践为基础，得出实证见解。一手资料包括对临床研究人员、生产专家、支付方和治疗中心营运经理的结构化访谈，旨在了解生产能力限制、供应链风险和推广障碍等方面的实际观点。二手资料分析涵盖同行评审文献、监管指导文件、会议记录和企业资讯披露，以全面检验临床疗效、安全性趋势和技术进步。

策略挑战的整合表明，需要提高製造韧性、产生证据并与支付方合作，以满足科学预期并实现更广泛的获取。

总之，CAR-T细胞疗法正处于一个关键的转折点，科学创新、生产能力和商业策略必须协调一致，才能为患者带来更广泛的益处。结构工程和下一代设计方面的技术进步不断拓展治疗的可能性，但对供应链和政策变化的运作应对将决定这些治疗方法成为常规治疗方案的速度。监管的柔软性以及支付方参与基于结果的模式的意愿，是将临床获益转化为永续可及性的关键途径。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 CAR-T细胞疗法市场：依适应症划分

  • 白血病
    • 急性淋巴性白血病
    • 急性骨髓性白血病
  • 多发性骨髓瘤
  • 非何杰金氏淋巴瘤
    • 瀰漫性大B细胞淋巴瘤
    • 滤泡性淋巴瘤
    • 套细胞淋巴瘤

第九章 CAR-T细胞疗法市场（依细胞来源划分）

  • 同种
  • 自有住房

第十章 CAR-T细胞疗法市场（按世代划分）

  • 第一代
  • 第四代
  • 第二代
  • 第三代

第十一章：依治疗阶段分類的CAR-T细胞疗法市场

  • 主要治疗
  • 復发/难治性

第十二章 CAR-T细胞疗法市场（以标靶抗原划分）

  • BCMA
  • CD19

第十三章 CAR-T细胞疗法市场：依最终用户划分

  • 学术研究机构
  • 医院
  • 门诊癌症治疗中心
  • 专科诊所

第十四章 CAR-T细胞疗法市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 CAR-T细胞疗法市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 CAR-T细胞疗法市场：按国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章 美国CAR-T细胞疗法市场

第十八章 中国CAR-T细胞疗法市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbClon Inc.
  • Adaptimmune Therapeutics
  • Allogene Therapeutics
  • Anixa Biosciences, Inc.
  • Autolus Therapeutics
  • Baylor College of Medicine
  • Bellicum Pharmaceuticals, Inc
  • BioAtla Inc.
  • Bluebird Bio
  • Caribou Biosciences, Inc.
  • Cellectis SA
  • Celyad Oncology
  • DH Life Sciences, LLC.
  • Fate Therapeutics, Inc.
  • Immatics NV
  • Innovative Cellular Therapeutics
  • JW Therapeutics,Co., Ltd.
  • Legend Biotech Inc.
  • Miltenyi Biotec
  • Novartis AG
  • Poseida Therapeutics
  • Precision BioSciences
  • Sana Biotechnology, Inc.
  • Sorrento Therapeutics
  • Tessa Therapeutics Pte Ltd.
  • uBriGene Biosciences Inc.
Product Code: MRR-1E2F1ED7E6AA

The CAR T-cell Therapy Market was valued at USD 5.19 billion in 2025 and is projected to grow to USD 5.98 billion in 2026, with a CAGR of 16.20%, reaching USD 14.87 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.19 billion
Estimated Year [2026] USD 5.98 billion
Forecast Year [2032] USD 14.87 billion
CAGR (%) 16.20%

A concise strategic orientation to CAR T-cell therapy integrating scientific progress, manufacturing realities, regulatory dynamics, and commercial access considerations

The landscape of CAR T-cell therapy sits at the intersection of cutting-edge immuno-oncology science and complex commercial execution. This executive summary synthesizes clinical progress, translational innovations, regulatory momentum, manufacturing maturation, and shifting care delivery models that collectively define the current state of CAR T field. It is intended to orient executives, clinical leaders, investors, and policy makers to the forces shaping development priorities and operational decisions.

Beginning with a succinct review of therapeutic mechanisms and indication-specific clinical performance, the summary transitions to pragmatic considerations such as manufacturing capacity, supply chain resilience, and evolving site-of-care dynamics. Throughout, emphasis rests on actionable insights that link scientific advances to commercial feasibility. The narrative highlights how modular manufacturing platforms, antigen selection strategies, and next-generation constructs are translating into differentiated clinical profiles and new usage paradigms. In parallel, payor engagement and real-world evidence generation are emerging as critical determinants of access and uptake.

Taken together, the introduction frames subsequent sections by clarifying how discrete technological, regulatory, and economic developments are converging to reshape CAR T strategy across stakeholders, supporting informed decisions about investment, partnership, and operational design.

How technical, regulatory, manufacturing, and commercial shifts are jointly reconfiguring CAR T development pathways and patterns of patient access

CAR T-cell therapy is undergoing a series of transformative shifts that extend beyond incremental product improvements to alter the structure of development and delivery. Advances in vector engineering, costimulatory domain selection, and antigen targeting are expanding therapeutic applicability while simultaneously influencing safety and durability profiles. These technical evolutions are complemented by manufacturing innovations such as decentralized and automated platforms that shorten production timelines and lower per-dose operational complexity. As these technical shifts progress, they create opportunities for novel commercial models that blend centralized expertise with point-of-care delivery.

Regulatory pathways are adapting in parallel, with agencies showing increasing willingness to consider real-world evidence and adaptive development strategies that balance expedited access with long-term safety monitoring. Meanwhile, health systems are recalibrating infrastructure to support CAR T administration outside of traditional inpatient settings, and payors are experimenting with outcome-based contracting to align cost and clinical benefit. Taken together, these shifts are driving a transition from single-product, high-cost interventions toward more scalable, evidence-driven programs that prioritize durable outcomes and broader patient access. Stakeholders that anticipate and align with these shifts will be better positioned to convert scientific leadership into sustained clinical and commercial impact.

Operational and strategic responses to 2025 tariff shifts that reshape supply chain resilience, manufacturing footprint decisions, and clinical trial logistics

The introduction of new United States tariff measures in 2025 has introduced a tangible variable into the economics and logistics of advanced cell therapies. Tariffs applied to imported raw materials, single-use components, and specific bioprocessing equipment increase upstream costs and create uncertainty in supplier selection. This dynamic incentivizes manufacturers and clinical centers to re-evaluate sourcing strategies, explore alternative suppliers, and consider increased vertical integration of critical supply chains. In the near term, procurement cycles lengthen as contracting teams assess tariff impacts and negotiate revised terms.

Beyond procurement, tariff-driven cost pressures influence decisions around manufacturing footprint. Organizations may accelerate investments in domestic manufacturing capacity to reduce exposure to cross-border duties, or they may pursue regional partnerships that localize key steps such as vector production and fill-finish operations. Clinical trial sponsors will need to revisit budgeting assumptions and may prioritize sites with proximate manufacturing or supply redundancy to mitigate logistical risk. In parallel, hospitals and outpatient centers that provide infusion services must adapt planning for consumable inventory and capital equipment procurement.

Taken together, tariffs in 2025 do not change the scientific promise of CAR T therapies, but they do alter operational calculus. Stakeholders who adopt proactive supply chain diversification, strategic onshoring where feasible, and collaborative contracting with suppliers will reduce disruption and preserve treatment continuity for patients while maintaining momentum in development and commercialization.

Segmentation-driven insights that reveal how indication, cell source, generation, therapeutic line, antigen targeting, and care settings define development and commercialization pathways

Detailed segmentation uncovers nuanced drivers and distinct opportunity spaces across therapeutic and delivery domains. By indication the market spans Leukemia, which itself is subdivided into Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia, Multiple Myeloma, and Non Hodgkin Lymphoma with Diffuse Large B Cell Lymphoma, Follicular Lymphoma, and Mantle Cell Lymphoma representing specific clinical subtypes; each indication carries unique response expectations, safety considerations, and evidentiary needs that influence trial design and commercialization strategy. Considering cell source, therapies derived from Allogeneic sources offer the promise of off-the-shelf dosing and faster time-to-treatment, while Autologous approaches remain prominent where individualized manufacturing aligns with established safety and efficacy precedents.

Generational differentiation also shapes clinical and operational profiles; First Generation constructs established proof of concept, Second Generation products introduced optimized costimulatory domains, Third Generation approaches combine multiple signaling elements for enhanced persistence, and Fourth Generation designs incorporate engineered functionalities such as cytokine expression or safety switches to broaden therapeutic potential. Line of therapy segmentation, including Frontline versus Relapsed Refractory use, dictates trial endpoints and payer conversations since earlier-line adoption prioritizes safety and long-term benefit whereas relapsed refractory contexts emphasize rapid response. Target antigen selection, notably BCMA and CD19, continues to drive indication-specific strategies and companion diagnostics development. Finally, end user segmentation across Academic Research Institutes, Hospitals, Outpatient Oncology Centers, and Specialty Clinics determines where investments in training, infrastructure, and care pathways will be most impactful, influencing rollout sequencing and provider partnerships.

How regional regulatory environments, manufacturing strategies, and care delivery capacity are directing differentiated CAR T access across global markets

Regional dynamics exert a powerful influence on regulatory expectations, manufacturing strategy, and care delivery models. In the Americas, dense networks of specialized treatment centers, a historically active venture ecosystem, and flexible regulatory pathways have catalyzed early clinical adoption and commercialization strategies that emphasize domestic manufacturing and real-world evidence generation. In contrast, Europe, Middle East & Africa presents a mosaic of regulatory regimes and heterogeneous reimbursement systems that require tailored health economic arguments and localized engagement plans, while also offering opportunities for regional manufacturing hubs that can serve multiple markets.

Asia-Pacific exhibits rapid capacity building, increasing domestic investment into cell therapy platforms, and an expanding pool of clinical trial sites that can accelerate patient accrual and comparative effectiveness research. Differences in infrastructure, workforce training, and reimbursement policy across these regions shape the pace and scale of access; as a result, manufacturers are adopting region-specific manufacturing footprints, regulatory strategies, and commercial partnerships to optimize launch sequencing and pricing models. Cross-regional collaboration, including licensing, co-development, and strategic manufacturing alliances, emerges as a practical pathway to reconcile global ambition with local realities and regulatory nuance.

Corporate strategies and collaborative models that drive competitive advantage through manufacturing scale, construct innovation, and integrated commercial support

Leading organizations in the CAR T ecosystem are advancing diversified portfolios across construct design, antigen targeting, and manufacturing modalities while pursuing strategic alliances to secure supply chains and broaden clinical reach. Industry participants are investing in modular, automated manufacturing platforms to reduce cycle times and improve reproducibility, and they are forging partnerships with academic centers and contract manufacturing organizations to expand capacity. Several companies are differentiating through next-generation engineering approaches that focus on enhancing persistence, reducing toxicities, and enabling multi-antigen targeting to address antigen escape.

At the same time, competitive dynamics reflect a balance between proprietary platform advantages and collaborative models that accelerate clinical development. Licensing agreements and co-development arrangements enable newer entrants to leverage established vector and manufacturing know-how, while incumbents seek to protect clinical differentiation through robust evidence generation and post-market surveillance. Commercial activities emphasize integrated value propositions that combine clinical training, reimbursement support, and outcomes tracking to de-risk adoption for health systems. As a result, competitive advantage increasingly derives from the ability to align scientific differentiation with scalable manufacturing and pragmatic commercialization support.

Action plans for industry leaders to link manufacturing resilience, evidence generation, payer engagement, and expanded site readiness to accelerate sustainable access

Industry leaders should prioritize a set of coordinated actions that connect scientific innovation with operational scalability and market access readiness. First, invest in flexible manufacturing architectures that support both autologous and allogeneic workflows, enabling rapid response to demand shifts and tariff-induced sourcing variability. Second, embed robust quality systems and supply redundancy for critical reagents and single-use components to minimize production interruptions and preserve patient schedules. Third, accelerate generation of real-world evidence by partnering with treatment centers and registries to document long-term outcomes and safety signals that underpin reimbursement discussions.

In parallel, companies should cultivate payer partnerships that explore outcome-based contracting and risk-sharing models aligned to durable response metrics, facilitating earlier adoption in frontline settings. From a clinical perspective, expand training programs and accreditation pathways to enable safe administration across a broader range of hospitals and outpatient oncology centers, thereby reducing time-to-treatment and improving patient access. Finally, adopt strategic regionalization for manufacturing and regulatory engagement that balances cost, speed-to-market, and local market access imperatives. These combined steps will strengthen resilience and align product value with health system needs, accelerating the conversion of scientific promise into patient benefit.

A transparent mixed-methods approach combining stakeholder interviews, literature synthesis, regulatory review, and operational case studies to inform practical recommendations

This research synthesized primary and secondary sources to produce evidence-based insights grounded in contemporary scientific and commercial practice. Primary inputs included structured interviews with clinical investigators, manufacturing experts, payers, and operational leaders across treatment centers to capture on-the-ground perspectives about capacity constraints, supply chain risks, and adoption barriers. Secondary analysis encompassed peer-reviewed literature, regulatory guidance documents, conference proceedings, and company disclosures to triangulate clinical efficacy, safety trends, and technological advancements.

Analytical methods combined thematic synthesis with comparative operational assessment to identify capacity bottlenecks and strategic responses. Case studies of manufacturing scale-up and decentralized production models informed practical recommendations. Throughout the methodology, emphasis was placed on transparency around data limitations, including the variable maturity of clinical evidence across indications and the evolving regulatory landscape. Sensitivity to regional regulatory differences and supply chain volatility guided scenario planning and risk mitigation suggestions. Ethical considerations and patient-centric outcomes remain central to the interpretive framework, and the research team employed rigorous validation steps to ensure credibility and relevance for decision-makers.

Synthesis of strategic imperatives showing that scientific promise requires manufacturing resilience, evidence generation, and payer engagement to achieve broader access

In conclusion, CAR T-cell therapy stands at a decisive inflection point where scientific innovation, manufacturing capability, and commercial strategy must align to deliver broader patient impact. Technical progress in construct engineering and next-generation designs continues to expand therapeutic potential, while operational responses to supply chain and policy changes will determine the pace at which those therapies become routine care options. Regulatory flexibility and payer willingness to engage around outcomes-based models are critical levers to translate clinical benefit into sustainable access.

Moving from promise to practice requires coordinated investments in manufacturing resilience, evidence generation, and clinical site readiness, together with proactive stakeholder engagement across regulators, payers, and providers. Organizations that synchronize technical differentiation with pragmatic operational design and regional strategy will capture the greatest clinical and commercial upside. Ultimately, the future of CAR T depends not only on molecular innovation but equally on the robustness of the systems that deliver these therapies to patients in need.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. CAR T-cell Therapy Market, by Indication

  • 8.1. Leukemia
    • 8.1.1. Acute Lymphoblastic Leukemia
    • 8.1.2. Acute Myeloid Leukemia
  • 8.2. Multiple Myeloma
  • 8.3. Non Hodgkin Lymphoma
    • 8.3.1. Diffuse Large B Cell Lymphoma
    • 8.3.2. Follicular Lymphoma
    • 8.3.3. Mantle Cell Lymphoma

9. CAR T-cell Therapy Market, by Cell Source

  • 9.1. Allogeneic
  • 9.2. Autologous

10. CAR T-cell Therapy Market, by Generation

  • 10.1. First Generation
  • 10.2. Fourth Generation
  • 10.3. Second Generation
  • 10.4. Third Generation

11. CAR T-cell Therapy Market, by Line Of Therapy

  • 11.1. Frontline
  • 11.2. Relapsed Refractory

12. CAR T-cell Therapy Market, by Target Antigen

  • 12.1. BCMA
  • 12.2. CD19

13. CAR T-cell Therapy Market, by End User

  • 13.1. Academic Research Institutes
  • 13.2. Hospitals
  • 13.3. Outpatient Oncology Centers
  • 13.4. Specialty Clinics

14. CAR T-cell Therapy Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. CAR T-cell Therapy Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. CAR T-cell Therapy Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States CAR T-cell Therapy Market

18. China CAR T-cell Therapy Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AbClon Inc.
  • 19.6. Adaptimmune Therapeutics
  • 19.7. Allogene Therapeutics
  • 19.8. Anixa Biosciences, Inc.
  • 19.9. Autolus Therapeutics
  • 19.10. Baylor College of Medicine
  • 19.11. Bellicum Pharmaceuticals, Inc
  • 19.12. BioAtla Inc.
  • 19.13. Bluebird Bio
  • 19.14. Caribou Biosciences, Inc.
  • 19.15. Cellectis SA
  • 19.16. Celyad Oncology
  • 19.17. DH Life Sciences, LLC.
  • 19.18. Fate Therapeutics, Inc.
  • 19.19. Immatics N.V.
  • 19.20. Innovative Cellular Therapeutics
  • 19.21. JW Therapeutics,Co., Ltd.
  • 19.22. Legend Biotech Inc.
  • 19.23. Miltenyi Biotec
  • 19.24. Novartis AG
  • 19.25. Poseida Therapeutics
  • 19.26. Precision BioSciences
  • 19.27. Sana Biotechnology, Inc.
  • 19.28. Sorrento Therapeutics
  • 19.29. Tessa Therapeutics Pte Ltd.
  • 19.30. uBriGene Biosciences Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CAR T-CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CAR T-CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CAR T-CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES CAR T-CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA CAR T-CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CAR T-CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY DIFFUSE LARGE B CELL LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY DIFFUSE LARGE B CELL LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY DIFFUSE LARGE B CELL LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FOLLICULAR LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FOLLICULAR LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FOLLICULAR LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY MANTLE CELL LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY MANTLE CELL LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY MANTLE CELL LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ALLOGENEIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ALLOGENEIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ALLOGENEIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY AUTOLOGOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY AUTOLOGOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FIRST GENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FIRST GENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FIRST GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FOURTH GENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FOURTH GENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FOURTH GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY SECOND GENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY SECOND GENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY SECOND GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY THIRD GENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY THIRD GENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY THIRD GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FRONTLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FRONTLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FRONTLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY RELAPSED REFRACTORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY RELAPSED REFRACTORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY RELAPSED REFRACTORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY BCMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY BCMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY BCMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY CD19, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY CD19, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY CD19, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY OUTPATIENT ONCOLOGY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY OUTPATIENT ONCOLOGY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY OUTPATIENT ONCOLOGY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. GCC CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. GCC CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 161. GCC CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 162. GCC CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 163. GCC CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 164. GCC CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 165. GCC CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 166. GCC CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
  • TABLE 167. GCC CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. G7 CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. G7 CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 188. G7 CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 189. G7 CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 190. G7 CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 191. G7 CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 192. G7 CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 193. G7 CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
  • TABLE 194. G7 CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. NATO CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. NATO CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 197. NATO CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 198. NATO CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 199. NATO CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 200. NATO CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 201. NATO CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 202. NATO CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
  • TABLE 203. NATO CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES CAR T-CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA CAR T-CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 220. CHINA CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 221. CHINA CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)